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correlates to bone loss and predicts the efficacy of
antiresorptive therapy in pre- and post-menopausal
non-metastatic breast cancer patients
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Summary The aim of this study was to determine the correlation between changes in collagen metabolites (ICTP, mature cross-linked carboxy-
terminal telopeptide of type collagen; PINP, the amino-terminal propeptide of type procollagen) and bone mineral density (BMD) in 206
pre- and post-menopausal breast cancer patients with non-metastatic disease. All patients received adjuvant cancer treatment -
premenopausal patients chemotherapy and post-menopausal patients anti-oestrogens. In addition, the patients were also randomized to receive
oral clodronate 1600 mg daily for 3 years. BMD was measured at baseline and at 1 and 2 years, the collagen metabolites at baseline and at 1
year. There was a highly significant negative correlation between the changes in PINP and BMD in lumbarspine and femoral neckfrom baseline
to 12 months in all patients (r, = - 0.68, P< 0.0001, and - 0.45, P< 0.0001, respectively), and in pre- and post-menopausal patients separately.
The changes in PINP levels at 12 months predict further changes in BMD at 24 months (rs = - 0.70, P < 0.0001, and - 0.51, P < 0.0001,
respectively). ICTP and BMD changes correlated significantly only in lumbar spine of premenopausal patients who developed rapid bone loss
due to chemotherapy-induced amenorrhoea (rs = - 0.34, P = 0.0003). The PINP levels at 12 months were significantly lower in the clodronate
group than in the control group (P< 0.0001). Our results indicate that PINP is a sensitive marker of bone turnover rate. Changes in PINP levels
significantly predicted changes in BMD and correlated with the antiresorptive efficacy of clodronate treatment.
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Post-menopausal osteoporosis is a common disorder. After
menopause, bone turnover rate increases rapidly as a result of
oestrogen deficiency. There is an imbalance between resorption
and formation, the resorption exceeding the formation, with accel-
erated bone loss as a result (Parfitt, 1979). Early menopause, low
bone mass at menopause and fast rate of bone loss after
menopause are the risk factors of osteoporosis. BMD is the most
accurate way of measuring bone mass and diagnosing osteo-
porosis. However, the rate of bone loss after menopause varies
significantly from one woman to another and can not be predicted
by a single BMD measurement (Christiansen et al, 1987, 1990;
Hansen et al, 1991). Serial BMD measurements are needed, but
because of the relatively small changes in bone mass per year in
comparison with the precision of the measurement methods, it
may take a long time to predict the rate of bone loss with BMD
measurements (Riggs et al, 1986; Hansen et al, 1990; Pouilles et
al, 1993, 1995).
An intriguing possibility would therefore be to use biochemical
markers of bone turnover as indicators of the rate of bone loss.
Both resorption (urinary excretions of hydroxyproline, pyridino-
line cross-links ofcollagen, and cross-linked telopeptides oftype I
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collagen) and formation markers of bone (circulating concentra-
tions of alkaline phosphatase, osteocalcin and carboxy-terminal
propeptide of type I procollagen) increase significantly after
menopause. During hormone replacement therapy, these markers
decrease to the premenopausal level (Johansen et al, 1987, 1988;
Riis et al, 1988; Hassager et al, 1991; Riis, 1991, 1993; Uebelhart
et al, 1991; Garnero et al, 1994a; Bonde et al, 1995). A decrease in
bone turnover markers has also been documented during calci-
tonin and bisphosphonate treatment in post-menopausal osteo-
porosis (Garnero et al, 1994b; Gertz et al, 1994; Nielsen et al,
1994; Lyritis et al, 1995; Pedrazzoni et al, 1995). The best correla-
tion between bone markers and bone loss rate, so far, has been
demonstrated by combining measurements of several resorption
and formation markers (Christiansen et al, 1987, 1990; Riis, 1991,
1993; Uebelhart et al, 1991; Pansini et al, 1992; Seibel et al, 1993).
As type I collagen is the most common protein in the skeleton,
comprising about 90% of the organic matrix in bone tissue
(Melkko et al, 1990), assays of the turnover of this protein could
be good markers of bone turnover. A radioimmunoassay of the
breakdown of mature type I collagen ICTP has recently been
shown to be a sensitive marker of bone resorption in different
diseases involving increased pathological degradation of collagen
(Elomaa et al, 1992; Hakala et al, 1993; Risteli et al, 1993; De la
Piedra et al, 1994; Kylmala et al, 1995; Blomqvist et al, 1996). The
results of ICTP as a resorption marker in post-menopausal osteo-
porosis have been conflicting (Charles et al, 1994; Gamero et al,
1994b; Hassager et al, 1994; Valimaki et al, 1994; Pedrazzoni et
al, 1995). Amino-terminal propeptide oftype I procollagen, PINP,
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is a new marker intended to reflect the synthesis oftype I collagen
(Melkko et al, 1996). In osteoporosis, the changes in PINP levels
follow the concentrations ofosteocalcin and alkaline phosphatase,
but differ from the values of PICP, which is the carboxy-terminal
analogue of PINP (Sharp et al, 1996).
We have previously reported the results of BMD measurements
in 206 primary early-stage breast cancer patients without
metastases (Saarto et al, 1997a and b). Briefly, bone loss in
premenopausal patients correlated significantly with the ovarian
dysfunction induced by adjuvant chemotherapy. The most marked
bone loss was seen in those patients rendered amenorrhoeic by
chemotherapy. Clodronate significantly reduced the bone loss both
in lumbar spine and in femoral neck in all premenopausal women
(in the control group - 5.9% and - 0.2% and in the clodronate
group - 2.2% and + 0.9% respectively) and in amenorrhoeic
patients separately (in the control group - 9.5% and - 4.6% and in
the clodronate group - 5.9% and - 0.4% respectively). In post-
menopausal patients, anti-oestrogen treatment with tamoxifen or
toremifene seemed to prevent the development of post-
menopausal osteoporosis. Clodronate treatment significantly
improved BMD of lumbar spine and femoral neck in post-
menopausal patients (in the control group - 0.5% + 0.5% and in
the clodronate group + 2.9% and + 3.7% respectively). Here, we
wanted to find out in the same patients whether changes in PINP
and ICTP levels may (1) correlate with BMD behaviour and (2)
predict the efficacy ofclodronate therapy.
MATERIAL AND METHODS
Patients and methods
The study population consisted of 206 pre- and post-menopausal
women with operable breast cancer and histologically proven axil-
lary metastases, without haematogenic metastases. Eligible for the
analyses were patients who were disease free at the time of
measurement of BMD and collagen metabolites. In addition,
patients having bone metastases within 6 months after measure-
ment of BMD and collagen metabolites were excluded from the
analyses. Baseline adjuvant cancer treatment was six cycles of
CMF chemotherapy for premenopausal patients (cyclophos-
phamide 600 mg m-2, methotrexate 40 mg m-2 and 5-fluorouracil
600 mg m-2) and anti-oestrogens for post-menopausal patients
(tamoxifen 20 mg or toremifene 60 mg per day) for 3 years. All
patients underwent surgery with axillary evacuation and total
mastectomy or breast-conserving resection and post-operative
radiotherapy. All patients were randomized to receive oral
clodronate (Bonefos, Leiras) 1600 mg daily for 3 years or to a
control group. After chemotherapy, the premenopausal patients
were divided into two groups according to menstrual function at
1 yearoffollow-up: menstruating (regularly orirregularly) or amen-
orrhoeic patients. Fast bone losers were defined as patients who lost
BMD by more than 3% per year. The BMD changes during the trial
of2 years have been previously reported (Saarto et al, 1997a andb).
Biochemical measurements were performed at the start of the
study and at 12 months. All serum samples were stored at - 20°C.
ICTP and PINP reflect degradation and synthesis, respectively, of
type I collagen, the predominant collagen in bone matrix. The
methods for the PINP and ICTP assays have been described else-
where (Risteli et al, 1993; Melkko et al, 1996). The reference
interval ofICTP for adult women is 1.7-4.6 ,ug 1-', and that ofPINP
19-84 gg 1-1. The intra- and interassay coefficients of variation are
3.1-8.5% for PINP, and 2.8-6.2% and 4.1-7.9% for ICTP respec-
tively (Risteli et al, 1993; Melkko et al, 1996). Bone mineral
density (BMD, g cm-2) was measured by dual-energy X-ray absorp-
tiometry (DXA) using a Hologic QDR-1000 densitometer
(Hologic, Waltham, MA, USA). BMD was measured at the lumbar
vertebrae (LI-L4) and femoral neck in the right femoral area
before initiation oftherapy and at 1 and 2 years. The coefficients of
variation for precision of the BMD measurements in the lumbar
vertebrae and femoral neck were 0.9% and 1.2% respectively.
Table 1 Correlation between baseline levels of collagen markers and baseline level of BMD or changes in BMD at 1 and 2 years. Spearman's rank-order
correlation and 95% confidence intervals
Baseline collagen Baseline BMD BMD change in LS BMD change in FN
markers
LS FN 1 year 2 year 1 year 2 year
Allpatients
PINP r5=-0.26 r=-0.23 r =0.32 r =0.30 NS NS
(-0.39, - 0.12) (-0.36, - 0.09) (0.19, 0.44) (0.16, 0.43)
(P= 0.0002) (P = 0.0009) (P < 0.0001) (P < 0.0001)
ICTP NS NS r = 0.18 NS NS NS
(0.41, 0.31)
(P = 0.01)
Premenopausal patients
PINP NS NS NS NS NS NS
ICTP NS NS NS NS NS NS
Post-menopausalpatients
PINP r =- 0.27 NS rS =0.32 r = 0.34 NS NS
(-0.45, - 0.07) (0.12, 0.50) (0.13, 0.52)
(P = 0.01) (P = 0.002) (P = 0.002)
ICTP NS NS NS NS NS NS
LS, lumbar spine; FN, femoral neck.
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Table 2 Correlation between BMD changes at 1 and 2 years and changes in the levels of collagen markers from baseline to those at 12 months. Spearman's
rank-order correlation and 95% confidence intervals
Change in collagen BMD change in LS BMD change in FN
markers
1 year 2 year 1 year 2 year
Allpatients
PINP r=-O.68 r =-0.70 rs=-0.45 rs=-0.51
(-0.75, - 0.60) (-0.77, - 0.61) (-0.56, - 0.33) (-0.61, - 0.39)
(P < 0.0001) (P < 0.0001) (P < 0.0001) (P < 0.0001)
ICTP r0 =-0.27 r =-0.31 NS r5=-0.25
(-0.40, - 0.13) (-0.43, - 0.16) (- 0.39, - 0.10)
(P= 0.0001) (P< 0.0001) (P= 0.0009)
Premenopausal
PINP r =-0.60 r =-0.60 r =-0.38 r =-0.43
(- 0.71, - 0.46) (- 0.72, - 0.45) (- 0.53, - 0.21) - 0.58, - 0.23)
(P < 0.0001) (P< 0.0001) (P< 0.0001) (P< 0.0001)
ICTP r~=-0.34 rs=-0.38 NS r =-0.30
(-0.50, - 0.16) (-0.54, - 0.19) (-0.48, - 0.10)
(P= 0.0003) (P= 0.0002) (P= 0.003)
Post-menopausal
PINP r =-0.59 rs=-0.62 r=-0.34 rs=-0.52
(-0.71, - 0.43) (-0.74, - 0.46) (-0.51, - 0.14) (-0.67, - 0.34)
(P < 0.0001) (P < 0.0001) (P = 0.001) (P < 0.0001)
ICTP NS NS NS NS
LS, lumbar spine; FN, femoral neck.
Statistical methods
Of the 206 eligible patients, nine patients had missing values for
baseline PINP level and two at 12 months, ten patients had missing
values for baseline ICTP and three at 12 months. BMD measure-
ment was available in 179 patients at 2 years after the start of the
study. Cases with missing laboratory values were excluded from
those analyses only when these values were needed. Analyses
were performed for all patients and for the pre- and post-
menopausal patients separately. The differences in marker values
between premenopausal patients with preserved menstruation or
with induced amenorrhoea and the effect of clodronate treatment
on marker change were tested with the Mann-Whitney test. The
correlations between marker levels and the BMD were assessed
using Spearman's rank-order correlation coefficient (r). Marker
change was calculated as marker level at 12 months of follow-up
divided by the baseline level. Confidence intervals (95%) for rs
were calculated with the CIA statistical software (Gardner et al,
1989). Because of the problems of multiple comparisons, the
significance level was set at 0.01.
RESULTS
Correlation between type I collagen metabolites and
BMD at baseline
The median PINP value at baseline was 42.8 jig 1-' (range
11.4-169.4 jig 1-1), in premenopausal patients 40.6 jig 1-' (range
11.4-90.6 jig 1-1) and in post-menopausal patients 45.4 jg 1-1
(range 21.2-169.4 ,ug 1-'). Baseline PINP level was significantly
higher in the post-menopausal than in the premenopausal patients
(P = 0.008), but there was no baseline differences between the
premenopausal patients who preserved menstruation and those
who became amenorrhoeic after chemotherapy. Baseline PINP
values were within the reference interval in 191 patients (97%).
The baseline PINP concentration correlated negatively to baseline
BMD in lumbar spine and in femoral neck (r = -0.25, P = 0.0002,
andrs = - 0.23, P = 0.0009, respectively). The negative correlation
between baseline lumbar spine BMD and PINP level was also
significant in post-menopausal patients, but not in premenopausal
patients (Table 1).
The medianconcentration ofICTP atbaseline was 3.8 ,ug 1- (range
1.6-17.2 ,ug 1-'), in premenopausal patients 3.5 ,ug 1-1 (range 1.6-
8.3 jig 1-1) and in post-menopausal 4.0 ,ug 1-' (range 1.8-17.2 jig 1-').
Baseline ICTP level was significantly higherinpost-menopausal than
in premenopausal patients (P = 0.004), with no baseline differences
between the premenopausal patients who, after chemotherapy,
menstruated or were amenorrhoeic. The baseline ICTP value was
within the reference interval in 153 patients (78%). The baseline
ICTP concentrations did not correlate with baseline BMD (Table 1).
Prediction of bone loss by type I collagen metabolites
at baseline
The baseline PINP level correlated positively with the BMD
changes in the lumbar spine at 1 and 2 years (rS = 0.32, P < 0.0001,
and rs = 0.30, P < 0.0001, respectively), but not with those in the
femoral neck. The significant correlations with BMD in lumbar
spine at 1 and 2 years were also seen in the group of post-
menopausal, but not in that ofpremenopausal, patients. A marginal
positive correlation was also seen between the baseline ICTP level
and the BMD change in lumbar spine at 1 year(rs = 0.18, P = 0.01)
(Table 1).
British Journal of Cancer (1998) 78(2), 240-245 0 Cancer Research Campaign 1998PINP correlation to bone mineral density 243
i I
O.
O.% I I
I I .~~~~~
I
0 +100+200 +500
APINP (%)
Figure 1 Correlation between changes in lumbar spine BMD and PINP
levels from baseline to 12 months in all patients (mean + s.d.). Regression
lines in all patients y= 117 842 - 9886*x, r2 = 0.414; in premenopausal
patients y= 116 337 - 9329*x, r2 = 0.289; in post-menopausal patients
y = 116 119 - 8709*x, r2 = 0.360; in clodronate-treated patients
y = 112 583 - 6893*x, r2 = 0.320; and in control patients
y= 123 586 - 12 765*x, r2 = 0.436
Prediction of bone loss by changes in type I collagen
metabolites
The Spearman's rank-order correlation coefficients between the
changes observed in the markers from baseline to 12 months and
the BMD changes in lumbar spine and femoral neck at 1 and 2
years are shown in Table 2 and Figure 1. There was a highly signif-
icant negative correlation between PINP changes from baseline to
12 months and BMD changes to 1 and 2 years in all patients in
lumbar spine (rs = - 0.68, P < 0.0001, and - 0.70, P < 0.0001) and
femoral neck (rs = - 0.45, P < 0.0001, and - 0.51, P < 0.0001), and
in pre- and post-menopausal patients separately. The median
change in PINP level in all patients was - 6.7 gg 1-' (- 18.3%), in
premenopausal patients + 0.6 gg 1-' (+ 1.4%), in post-menopausal
patients - 17.6 tg 1-1 (-41.8%) and separately in menstruating and
amenorrhoeic premenopausal patients - 4.6 jig 1-' (- 15.7%) and
+ 28.4 jig 1-' (+ 61.0%) respectively (Figure 2).
ICTP change correlated significantly negatively with lumbar
spine BMD change at 1 and 2 years in all patients (rs = - 0.27,
P = 0.0001, and - 0.31, P < 0.0001) and in premenopausal patients
(rs = - 0.34, P = 0.0003, and - 0.38, P = 0.0002), but with femoral
neck only at 2 years. No correlation was seen in post-menopausal
patients (Table 2). The median change in ICTP levels in all patients
was - 0.7 jig 1-' (- 22.8%), in premenopausal patients - 0.3 jig 1-'
(- 14.8%), in post-menopausal patients - 1.0 jg 1-' (- 25.0%)
and in menstruating and amenorrhoeic premenopausal patients
- 0.6 ,ug 1-' (- 20.0%) and + 0.05 ,ug 1-' (+ 1.5%) respectively.
+200 +250 +450 +800
Figure 2 Correlation between PINP level changes and changes in lumbar
spine BMD from baseline to 12 months in amenorrhoeic and menstruating
premenopausal patients (mean + s.d.)
Correlation between type I collagen metabolites at
12 months and BMD changes
PINP levels at 12 months correlated significantly negatively to
BMD changes at and 2 years in lumbar spine (rs = - 0.54, P <
0.0001, and rs = - 0.59, P < 0.0001) and femoral neck (rs = - 0.39,
P < 0.0001, and rs = - 0.47, P < 0.0001) in all patients; in the
premenopausal women in lumbar spine (r = - 0.46, P < 0.0001,
and r, = - 0.50, P < 0.0001) and femoral neck (rs = - 0.37,
P < 0.0001, and rs = - 0.39, P < 0.0001); and in post-menopausal
patients in lumbar spine (r = 0.45, P < 0.0001, and r = 0.51,
P < 0.0001) and femoral neck (rs = - 0.23, P = 0.026, and
rs
= - 0.48, P < 0.0001).
A marginal negative correlation was also seen in premenopausal
patients between ICTP levels at 12 months and BMD changes at 1
and 2 years in lumbar spine (rs = - 0.26, P = 0.005, and - 0.34,
P = 0.0007) and in femoral neck (rs = - 0.20, P = 0.03 and - 0.29,
P = 0.004), but not in post-menopausal patients.
Clodronate vs control group
Baseline values ofPINP were similar in the clodronate and control
groups. PINP levels at 12 months were significantly lower in the
clodronate group than in the control group, in all patients and also
in pre- and post-menopausal patients (P < 0.0001, 0.0003 and
< 0.0001 respectively). In all patients, median PINP levels
decreased in the clodronate and control groups by 14.6jig -1
(- 38.7%) and 0.7 jtg 1- (- 1.7%) respectively (P < 0.0001). In
premenopausal patients, median PINP levels decreased with
clodronate by 5.6 jg 1-1 (- 16.8%), but increased without it by
9.2 tg 1-' (+ 29.5%) (P = 0.0005): in menstruating patients, the
corresponding changes were - 11.6jg 1-1 (- 27.6%) with and
- 2.1 ,ug 1-' (- 3.6%) without clodronate, and in amenorrheic
patients + 0.7 jg 1-' (+ 1.8%) with and + 34.5 jg 1-' (+ 83.3%)
without clodronate (P = 0.003 and 0.007). In post-menopausal
patients, median PINP levels decreased by 30.8 jg 1-1 (- 60.8%)
with and by 12.4 jg 1-1 (- 25.2%) without clodronate (P < 0.0001)
(Figure 3).
The clodronate and control groups did not differ from each other
by baseline or 12-month ICTP levels, nor by changes in ICTP
levels from the baseline to 12 months.
DISCUSSION
In the development of osteoporosis, the rate of bone loss after
menopause is at least as important as bone mass at menopause.
Women who have had rapid bone loss at menopause lose, on
average, twice the amount of bone mass over 12 years after
menopause than normal bone losers (Hansen et al, 1991). Several
attempts have been made to identify rapid bone losers by
measuring biochemical markers of bone turnover. The best corre-
lation between bone markers and bone loss rate, so far, has been
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Figure 3 Mean (± s.d.) PINP level changes from baseline to 12 months with
(-0-) and without (-{-:) clodronate treatment in pre- and post-menopausal
patients
demonstrated by combining several resorption and formation
markers (Christiansen et al, 1987, 1990; Riis, 1991, 1993;
Uebelhart et al, 1991; Pansini et al, 1992; Seibel et al, 1993).
Metabolites of type I collagen released into the circulation during
bone formation or resorption are novel markers of bone turnover.
The assays of the amino-terminal propeptide of type I procollagen
(PINP) and of the pyridinoline or pyrrole cross-linked carboxy-
terminal telopeptide of type I collagen (ICTP) have been devel-
oped to reflect the synthesis of and the degradation of type I
collagen respectively (Risteli et al, 1993; Melkko et al, 1996).
Our study implies that the measurement of the PINP level
change is an effective method to determine the rate ofbone loss. In
this study, the changes in PINP levels from baseline to 12 months
significantly correlated with the changes in BMD of lumbar spine
and femoral neck in pre- and post-menopausal women during the
same time and further predicted the changes in BMD at 2 years.
These correlations were seen both in pre- and in postmenopausal
patients separately. In the present study, the PINP level at 12
months also correlated significantly to BMD changes. However,
because of the wide individual variation in PINP levels, the
changes in PINP from baseline are more useful parameters in eval-
uation of bone turnover rate than PINP levels at 12 months.
The response of PINP on clodronate treatment in our study was
concordant with the response of other bone turnover markers on
antiresorptive treatment in previous studies (Garnero et al, 1994b;
Gertz et al, 1994; Nielsen et al, 1994; Lyritis et al, 1995;
Pedrazzoni et al, 1995). In the present study, PINP levels
decreased more significantly in the clodronate-treated patients
than in the control group. This was seen both in pre- and post-
menopausal patients. Similar PINP level decreases have previ-
ously been reported during oestrogen replacement therapy in
post-menopausal women. The circulating concentration of PINP
decreased by 40% during the oestrogen replacement therapy
reported by Sharp et al (1996), while in our post-menopausal
patients anti-oestrogen treatment with clodronate decreased the
PINP level by 61% and the anti-oestrogen alone by 25%.
Baseline PINP level was significantly higher in post-menopausal
patients than in premenopausal patients, reflecting higher bone
turnover rate in post-menopausal women. In the case of vertebral
osteoporosis, patients with higher bone turnover rate responded
better to calcitonin treatment than patients with lower turnover rate
(Civitelli et al, 1988). Similarly, in the present study, the baseline
PINP levels correlated positively to BMD changes in lumbar spine
in post-menopausal patients, the higher the baseline PINP level the
better the response to antiresorptive treatments (anti-oestrogens,
clodronate). However, this correlation was only seen in post-
menopausal women, which reflects that the rate of bone turnover
before menopause is not correlated to that after menopause.
ICTP and BMD changes correlated significantly only in lumbar
spine of premenopausal women whose rapid bone loss was a
consequence of chemotherapy-induced amenorrhoea. Baseline
ICTP level did not predict future changes in BMD, even though it
was significantly higher in post-menopausal patients than in
premenopausal patients. Neither was the efficacy of antiresorptive
treatments correlated to the decrease in ICTP level. This finding
agrees with previous ICTP reports in osteoporosis, in which ICTP
reflected bone resorption rate, but the sensitivity was too low to
predict small changes in BMD (Charles et al, 1994; Garnero et al,
1994b; Hassager et al, 1994; Pedrazzoni et al, 1995).
Our results indicate that the amino-terminal propeptide oftype I
procollagen (PINP) is a sensitive marker of bone metabolic
activity. Changes in PINP levels significantly correlated with
BMD changes and predicted further changes in BMD. The
changes in PINP level also reflected the efficacy of antiresorptive
treatment with clodronate.
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